TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) is one of 236 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its peers? We will compare TriSalus Life Sciences to related businesses based on the strength of its dividends, risk, profitability, analyst recommendations, earnings, institutional ownership and valuation.
Institutional and Insider Ownership
2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 32.8% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 15.1% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for TriSalus Life Sciences and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TriSalus Life Sciences | 0 | 0 | 5 | 1 | 3.17 |
| TriSalus Life Sciences Competitors | 1883 | 4845 | 9091 | 264 | 2.48 |
Profitability
This table compares TriSalus Life Sciences and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus Life Sciences | -219.71% | N/A | -192.99% |
| TriSalus Life Sciences Competitors | -548.71% | -134.21% | -26.36% |
Risk & Volatility
TriSalus Life Sciences has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences’ peers have a beta of 0.45, suggesting that their average stock price is 55% less volatile than the S&P 500.
Valuation & Earnings
This table compares TriSalus Life Sciences and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| TriSalus Life Sciences | $18.51 million | -$59.04 million | -1.67 |
| TriSalus Life Sciences Competitors | $1.02 billion | $9.23 million | -17.23 |
TriSalus Life Sciences’ peers have higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
TriSalus Life Sciences beats its peers on 9 of the 13 factors compared.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
